³ÁÔüÇÐƬ,deposit slicingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈýÔª¸´ºÏÒò×Ó,ternary complex factorsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ѪÇå·´Ó¦Ôª¼þ,serum response elementÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ½ºÔ­Ñù·Ö×Ó,collagen-like moleculesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÉÏÇ»¾²ÂöѹÆÈÕ÷,superior vena cava compression syndromeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÒÖÖÆÖ×ÁöÉú³¤,inhibition of tumor growthÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÆæÕýÏûÍ´Ìù,Qizhengxiaotong EmplastrumÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×Ô·¢ÐÔÖ×Áö,spontaneous tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µ²Ç¦,lead-alloy blockÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Õæ¿Õ¸ºÑ¹´ü,vacuum bag with negative pressureÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸¹ÅèÇ»ÌåĤ,thermoplastic sheet for patients with abdominal or pelvic tumorsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¿¹Ö×Áö°Ðµã,anti-tumor targetÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÖÎÁÆ´²,treatment couchÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼¡Çòµ°°×ÇáÁ´¼¤Ã¸/ÉúÀíѧ,Myosin-light-chain kinase/physiolÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µ¥ÌÇ·ÖÎö,monosaccharide analysisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶¯Ì¬ÊÊÐε÷Ç¿·ÅÁÆ,Four dimensional intensity modulated radiation therapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« PDZµ°°×,PDZ proteinsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×ÁöÖÎÁưеã,tumour therapeutic targetÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×ÁöÄÍҩϸ°û,MDR CellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ°û´¦Àí·½·¨,Cell Pretreatment MethodsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸¹Ë®Ï¸°ûѧ¼ì²é,ascetic cytological examinationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« °×Ê×ÎÚ×ÜÜÕ,general steroidal glycosides from Radix Cynanchi AuriculatiÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¾«È··ÅÉäÖÎÁÆ,precise radiotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ͬÖÖºÍÒìÖÖѪ¹ÜÄÚƤϸ°û,Autologous and xenogeneic endothelial cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« °×ÈýÏ©B4ÊÜÌå,Leukotriene B4 receptorsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« °©Ö¢ÖÎÓúÖ¸Êý,cancer cure indexÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×ÜÉ¢ÉäÒò×Ó,total scatter factorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×¼Ö±Æ÷É¢ÉäÒò×Ó,collimator scatter factorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×éÖ¯×î´ó¼ÁÁ¿±È,tissue-maximum ratioÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« СÕÕÉäÒ°,small fieldÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶ñÐÔÖ×ÁöÏà¹ØÒò×Ó,Tumor-related factorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ´Å¹²ÕñÒýµ¼µÄ¸ßÇ¿¶È¾Û½¹³¬Éù,magnetic resonance imaging guided high intensity focused ultrasoundÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ´Å¹²Õñ²âÎÂ,magnetic resonance imaging thermometryÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÁòËáÂð·È»ºÊÍƬ,morphine sulfate sustained-releease tabletsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ½æËá»·¼ºõ¥,cyclohexyl erucateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¿¹ÇÖÏ®»îÐÔ,Anti-invasive activityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ³ÉÈËÌÛÍ´,adult cancer painÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Èý½×ÌÝÕòÍ´,three-step analgesic laddersIÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Éñ¾­²¡ÀíÐÔ°©Í´,neuropathic cancer painÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« תÒÆÐÔ¼¹ËèѹÆÈÖ¢,metastatic spinal cord compressionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÑϽ÷·ÖÎö,rigorous analysisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶þά¿ÕÆøµçÀëÊÒ¾ØÕó,2D air vented ionization chambers arrayÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« SEZ6»ùÒò,SEZ6 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ʶ±ðÊÜÌå,recognition receptorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ½ð±êÖ²Èë,gold implantationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÆøµÀ¶ñÐÔÏÁÕ­,Malignant tracheal narrowÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÂÝ»·-ì¢Ëáõ¥À໯ºÏÎï,spiro-phosphonate derivateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Êý×Ö¼õÓ°¶¯ÂöÔìÓ°Êõ,Digital subtraction arteriography(DSA)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÉÏƤÐÔÖ×Áöϸ°û,epithelial cancer cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Àà±ðת»»ÖØ×é,class switch recombinationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ïà¿ØÕóÈÈÁÆ,phased array hyperthermia treatmentÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Âå·Ò´ýÒòƬ,ibuprofen-codeine phosphate tabletsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« °©Ï¸°ûתȾ,Cancer cell transferÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÔöÖ³Ðźŵ°°×,Proliferation of signalsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« MHC¢ñÀàÁ´Ïà¹Ø·Ö×ÓA/B,MHC¢ñ chain-related molecules A /BÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×éÖ¯²¹³¥,Organization CompensationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »ºÊÍÂð·È,sustained-release morphineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×ÁöѪ¹Ü°ÐÏòÖÎÁÆ,tumor vascular-targeted therapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¿¹Ñª¹ÜÐÂÉúÖƼÁ,antiangiogenic agentsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×ÁöѪ¹Ü×è¶ÏÖƼÁ,vascular-disrupting agentsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×ÁöÈÈ,Tumor related feverÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ΢Âö¹Üϵͳ,Micro vasculatureÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¾­Æ¤¸¹Ç»Éñ¾­´Ô×èÖÍÊõ,Percutaneous neurolytic coelial plexus blockÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÄÚ¹²Éú½ø»¯,symbiogenetic evolutionaryÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÎøËáÈí¹Ç¶àÌÇ,selenic acid cartilage polysaccharideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« DNAËðÉ˼ì²âµã·´Ó¦,DNA-damage checkpoint-responseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ½ðÄÉÃ׿ÕÐÄÇò,hollow gold nano-particlesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÔØÌåÖØ°ÐÏò,vector retargetingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ²¡¶¾ÐÞÊÎ,virus modificationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ñ¡ÔñÐÔĤ,Selective filmÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ir/IrO_x-pHµç¼«,Ir/IrO_x-pH electrodeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÎÛȾ,PollutionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ³¬Éù²¨,ultrasonicÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·ÅÉäÁÆ·¨,RadiotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÇÖÏ®,invasionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·ÅÁÆ,RadiotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ìÊ,enthalpyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ã×ÍÐÝìõ«,mitoxantroneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÍØÆËÌ濵,TopotecanÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ´Å¿Ø¹Ü,magnetronÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ñݽø,evolutionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·ÅÉäÍâ¿Æ,RadiosurgeryÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·ÅÉäÃâÒßÏÔÏñ,radioimmunoimagingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ±´·¥µ¥¿¹,bevacizumabÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö¬·¾ÈâÁö,LiposarcomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÄÚƤÒÖÖÆËØ,endostatinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¿É´ýÒò,CodeineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »Ò¶È,GrayÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×Áö/²¡Àíѧ,neoplasms/pathologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Á¦¶û·²,LifeinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Éú´æ,survivalÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« E-¸Æð¤ËØ,E-cadherinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Éñ¾­õ£°·Àà,ceramidesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ѫ¹ÜÄÚƤÁö,hemangioendotheliomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ѫ¹ÜÉú³ÉÒÖÖÆËØ,AngiostatinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹ý¼Ì,adoptiveÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö°©Îï,carcinogenÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ½âżÁª,uncouplingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÃâÒßżÁªÎï,immunoconjugateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸ß¼×»ù»¯,HypermethylationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«